Omega Therapeutics Names Kaan Certel as CEO

Dow Jones11-15

By Kailyn Rhone

Omega Therapeutics appointed Kaan Certel as chief executive officer of the Cambridge, Mass.-based biotechnology company.

Certel, who has been Omega's chief business officer since May, will succeed Mahesh Karande, who decided to leave the company for personal reasons.

Certel is an industry veteran with over 20 years of experience in the biopharmaceutical field and academia. Before Omega, he served as the chief business officer for BioCity Biopharma.

Under its new leadership, the company plans to focus its capital resources on three prioritized programs in obesity, regenerative medicine and metabolic indications that will leverage its value proposition.

Write to Kailyn Rhone at kailyn.rhone@wsj.com

(END) Dow Jones Newswires

November 14, 2024 17:28 ET (22:28 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483359601?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 06:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483359601","market":"sh","top_or_hot":-1,"title":"Omega Therapeutics Names Kaan Certel as CEO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kailyn Rhone \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/OMGA\">Omega Therapeutics</a> appointed Kaan Certel as chief executive officer of the Cambridge, Mass.-based biotechnology company. \n</p>\n<p>\n  Certel, who has been Omega's chief business officer since May, will succeed Mahesh Karande, who decided to leave the company for personal reasons. \n</p>\n<p>\n  Certel is an industry veteran with over 20 years of experience in the biopharmaceutical field and academia. Before Omega, he served as the chief business officer for BioCity Biopharma. \n</p>\n<p>\n  Under its new leadership, the company plans to focus its capital resources on three prioritized programs in obesity, regenerative medicine and metabolic indications that will leverage its value proposition. \n</p>\n<p>\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 14, 2024 17:28 ET (22:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omega Therapeutics Names Kaan Certel as CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmega Therapeutics Names Kaan Certel as CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 06:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Kailyn Rhone \n\n\nOmega Therapeutics appointed Kaan Certel as chief executive officer of the Cambridge, Mass.-based biotechnology company. \n\n\n  Certel, who has been Omega's chief business officer ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMGA","symbol_name":"Omega Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483359601","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483359601","pubTimestamp":1731623280,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Omega Therapeutics appointed Kaan Certel as chief executive officer of the Cambridge, Mass.-based biotechnology company.Certel, who has been Omega's chief business officer since May, will succeed Mahesh Karande, who decided to leave the company for personal reasons.Certel is an industry veteran with over 20 years of experience in the biopharmaceutical field and academia. Before Omega, he served as the chief business officer for BioCity Biopharma.Under its new leadership, the company plans to focus its capital resources on three prioritized programs in obesity, regenerative medicine and metabolic indications that will leverage its value proposition.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMGA":"Omega Therapeutics"},"translate_title":"Omega Therapeutics任命Kaan Certel为首席执行官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMGA":1},"content_text":"By Kailyn Rhone \n\n\nOmega Therapeutics appointed Kaan Certel as chief executive officer of the Cambridge, Mass.-based biotechnology company. \n\n\n  Certel, who has been Omega's chief business officer since May, will succeed Mahesh Karande, who decided to leave the company for personal reasons. \n\n\n  Certel is an industry veteran with over 20 years of experience in the biopharmaceutical field and academia. Before Omega, he served as the chief business officer for BioCity Biopharma. \n\n\n  Under its new leadership, the company plans to focus its capital resources on three prioritized programs in obesity, regenerative medicine and metabolic indications that will leverage its value proposition. \n\n\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 17:28 ET (22:28 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483359601"}